Motor Complications of Dopaminergic Medications in Parkinson's Disease

Maria Eliza Freitas; Christopher W. Hess; Susan H. Fox

doi:10.1055/s-0037-1602423

Seminars in Neurology, Table of Contents

Semin Neurol 2017; 37(02): 147-157
DOI: 10.1055/s-0037-1602423

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Motor Complications of Dopaminergic Medications in Parkinson's Disease

Maria Eliza Freitas

¹Division of Neurology, Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada

,

Christopher W. Hess

²Center for Movement Disorders and Neurorestoration, University of Florida, Gainesville, Florida

,

Susan H. Fox

¹Division of Neurology, Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada

› Author Affiliations

Abstract

Motor complications are a consequence of the chronic treatment of Parkinson's disease (PD) and include motor fluctuations (wearing-off phenomenon) and levodopa-induced dyskinesia. Both can have a significant impact on functionality and quality of life; thus, proper recognition and management is essential. The phenomenology and temporal relationship of motor complications to the schedule of levodopa dosing can be helpful in characterizing them. There are several therapeutic approaches to motor complications, including pharmacological and surgical options. The authors summarize the different types of motor complications according to phenomenology and the currently available medical treatments, including ongoing trials for the management of this condition.

Keywords

motor fluctuations - motor complications - levodopa-induced dyskinesia - Parkinson's disease

Full Text

References

References
1 Hornykiewicz O. A brief history of levodopa. J Neurol 2010; 257 (Suppl. 02) S249-S252
2 Aquino CC, Fox SH. Clinical spectrum of levodopa-induced complications. Mov Disord 2015; 30 (01) 80-89
3 Anderson E, Nutt J. The long-duration response to levodopa: phenomenology, potential mechanisms and clinical implications. Parkinsonism Relat Disord 2011; 17 (08) 587-592
4 Contin M, Martinelli P. Pharmacokinetics of levodopa. J Neurol 2010; 257 (Suppl. 02) S253-S261
5 Widnell K. Pathophysiology of motor fluctuations in Parkinson's disease. Mov Disord 2005; 20 (Suppl. 11) S17-S22
6 Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1977; 1 (8007): 345-349
7 Pahwa R, Lyons KE. Levodopa-related wearing-off in Parkinson's disease: identification and management. Curr Med Res Opin 2009; 25 (04) 841-849
8 Yoritaka A, Shimo Y, Takanashi M. , et al. Motor and non-motor symptoms of 1453 patients with Parkinson's disease: prevalence and risks. Parkinsonism Relat Disord 2013; 19 (08) 725-731
9 Thenganatt MA, Jankovic J. Parkinson disease subtypes. JAMA Neurol 2014; 71 (04) 499-504
10 Warren Olanow C, Kieburtz K, Rascol O. , et al; Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) Investigators. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord 2013; 28 (08) 1064-1071
11 Fox SH, Lang AE. Levodopa-related motor complications--phenomenology. Mov Disord 2008; 23 (Suppl. 03) S509-S514
12 Stocchi F, Rascol O, Kieburtz K. , et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010; 68 (01) 18-27
13 Chen H, Fang J, Li F, Gao L, Feng T. Risk factors and safe dosage of levodopa for wearing-off phenomenon in Chinese patients with Parkinson's disease. Neurol Sci 2015; 36 (07) 1217-1223
14 Cilia R, Akpalu A, Sarfo FS. , et al. The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa. Brain 2014; 137 (Pt 10): 2731-2742
15 Virmani T, Tazan S, Mazzoni P, Ford B, Greene PE. Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson's disease. J Clin Mov Disord 2016; 3 (01) 8 . doi: 10.1186/s40734-016-0036-9
16 Rahne K-E, Tagesson C, Nyholm D. Motor fluctuations and Helicobacter pylori in Parkinson's disease. J Neurol 2013; 260 (12) 2974-2980
17 Hashim H, Azmin S, Razlan H. , et al. Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson's disease. PLoS One 2014; 9 (11) e112330
18 Çamcı G, Oğuz S. Association between Parkinson's disease and Helicobacter pylori . J Clin Neurol 2016; 12 (02) 147-150
19 Niccolini F, Rocchi L, Politis M. Molecular imaging of levodopa-induced dyskinesias. Cell Mol Life Sci 2015; 72 (11) 2107-2117
20 Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991; 41 (2 ( Pt 1)): 202-205
21 Bjornestad A, Forsaa EB, Pedersen KF, Tysnes O-B, Larsen JP, Alves G. Risk and course of motor complications in a population-based incident Parkinson's disease cohort. Parkinsonism Relat Disord 2016; 22: 48-53
22 Scott NW, Macleod AD, Counsell CE. Motor complications in an incident Parkinson's disease cohort. Eur J Neurol 2016; 23 (02) 304-312
23 Colombo D, Abbruzzese G, Antonini A. , et al. The “gender factor” in wearing-off among patients with Parkinson's disease: a post hoc analysis of DEEP study. Sci World J 2015; 2015: 787451
24 Kumagai T, Nagayama H, Ota T, Nishiyama Y, Mishina M, Ueda M. Sex differences in the pharmacokinetics of levodopa in elderly patients with Parkinson disease. Clin Neuropharmacol 2014; 37 (06) 173-176
25 Nicoletti A, Arabia G, Pugliese P. , et al. Hormonal replacement therapy in women with Parkinson disease and levodopa-induced dyskinesia: a crossover trial. Clin Neuropharmacol 2007; 30 (05) 276-280
26 Sharma JC, Ross IN, Rascol O, Brooks D. Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight. Eur J Neurol 2008; 15 (05) 493-496
27 Müller T, Woitalla D, Saft C, Kuhn W. Levodopa in plasma correlates with body weight of parkinsonian patients. Parkinsonism Relat Disord 2000; 6 (03) 171-173
28 Strong JA, Dalvi A, Revilla FJ. , et al. Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease. Mov Disord 2006; 21 (05) 654-659
29 Lee J-Y, Cho J, Lee E-K, Park S-S, Jeon BS. Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease. Mov Disord 2011; 26 (01) 73-79
30 Kaplan N, Vituri A, Korczyn AD. , et al. Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease. J Mol Neurosci 2014; 53 (02) 183-188
31 Lee JY, Beom BJ. Risk factors for levodopa-induced dyskinesia. In: Fox SH, Brotchie JM. , eds. Levodopa-Induced Dyskinesia in Parkinson's Disease . London: Springer; 2014: 51-68
32 Dekker MCJ, Bonifati V, van Duijn CM. Parkinson's disease: piecing together a genetic jigsaw. Brain 2003; 126 (Pt 8): 1722-1733
33 Oliveri RL, Annesi G, Zappia M. , et al. Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. Neurology 1999; 53 (07) 1425-1430
34 Cheshire P, Bertram K, Ling H. , et al. Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease. Neurodegener Dis 2014; 13 (01) 24-28
35 Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM. The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease. Pharmacol Rev 2013; 65 (01) 171-222
36 Bateman DE, Levett K, Marsden CD. Sleep benefit in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 67 (03) 384-385
37 van Gilst MM, Bloem BR, Overeem S. “Sleep benefit” in Parkinson's disease: a systematic review. Parkinsonism Relat Disord 2013; 19 (07) 654-659
38 Hutton JT, Morris JL. Long-term evaluation of Sinemet CR in parkinsonian patients with motor fluctuations. Can J Neurol Sci 1991; 18 (04) 467-471
39 Yeh KC, August TF, Bush DF. , et al. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 1989; 39 (11) (Suppl. 02) 25-38
40 DeMaagd G, Philip A. Parkinson's disease and its management: part 4: treatment of motor complications. P&T 2015; 40 (11) 747-773
41 Gottwald MD, Aminoff MJ. Therapies for dopaminergic-induced dyskinesias in Parkinson disease. Ann Neurol 2011; 69 (06) 919-927
42 Okuma Y, Yanagisawa N. The clinical spectrum of freezing of gait in Parkinson's disease. Mov Disord 2008; 23 (02) (Suppl. 02) S426-S430
43 Espay AJ, Fasano A, van Nuenen BFL, Payne MM, Snijders AH, Bloem BR. “On” state freezing of gait in Parkinson disease: a paradoxical levodopa-induced complication. Neurology 2012; 78 (07) 454-457
44 Gazibara T, Pekmezovic T, Kisic-Tepavcevic D. , et al. Incidence and prediction of falls in Parkinson's disease: a prospective cohort study. Eur J Epidemiol 2015; 30 (04) 349-352
45 Malkani R, Zadikoff C, Melen O, Videnovic A, Borushko E, Simuni T. Amantadine for freezing of gait in patients with Parkinson disease. Clin Neuropharmacol 2012; 35 (06) 266-268
46 Kim YE, Yun JY, Yang HJ. , et al. Intravenous amantadine for freezing of gait resistant to dopaminergic therapy: a randomized, double-blind, placebo-controlled, cross-over clinical trial. PLoS One 2012; 7 (11) e48890
47 Lee J-Y, Oh S, Kim J-M. , et al. Intravenous amantadine on freezing of gait in Parkinson's disease: a randomized controlled trial. J Neurol 2013; 260 (12) 3030-3038
48 Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005; 62 (02) 241-248
49 Rascol O, Brooks DJ, Melamed E. , et al; LARGO study group. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with rasagiline given once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005; 365 (9463): 947-954
50 Rahimi F, Roberts AC, Jog M. Patterns and predictors of freezing of gait improvement following rasagiline therapy: A pilot study. Clin Neurol Neurosurg 2016; 150: 117-124
51 Espay AJ, Dwivedi AK, Payne M. , et al. Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial. Neurology 2011; 76 (14) 1256-1262
52 Devos D, Moreau C, Delval A, Dujardin K, Defebvre L, Bordet R. Methylphenidate: a treatment for Parkinson's disease?. CNS Drugs 2013; 27 (01) 1-14
53 Moreau C, Delval A, Defebvre L. , et al; Parkgait-II study group. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol 2012; 11 (07) 589-596
54 Bastide MF, Meissner WG, Picconi B. , et al. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. Prog Neurobiol 2015; 132: 96-168
55 Guridi J, González-Redondo R, Obeso JA. Clinical features, pathophysiology, and treatment of levodopa-induced dyskinesias in Parkinson's disease. Parkinsons Dis 2012; 2012: 943159
56 Poewe WH, Lees AJ, Stern GM. Dystonia in Parkinson's disease: clinical and pharmacological features. Ann Neurol 1988; 23 (01) 73-78
57 Tolosa E, Compta Y. Dystonia in Parkinson's disease. J Neurol 2006; 253 (Suppl. 07) VII7-VII13
58 Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord 1992; 7 (02) 117-124
59 Chen R, Ashby P, Lang AE. Stimulus-sensitive myoclonus in akinetic-rigid syndromes. Brain 1992; 115 (Pt 6): 1875-1888
60 Grötzsch H, Sztajzel R, Burkhard PR. Levodopa-induced ocular dyskinesia in Parkinson's disease. Eur J Neurol 2007; 14 (10) 1124-1128
61 LeWitt PA. Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease. Mov Disord 1998; 13 (04) 731-734
62 Linazasoro G, Van Blercom N, Lasa A, Indakoetxea B, Ruiz J. Levodopa-induced ocular dyskinesias in Parkinson's disease. Mov Disord 2002; 17 (01) 186-187
63 Rich MW, Radwany SM. Respiratory dyskinesia. An underrecognized phenomenon. Chest 1994; 105 (06) 1826-1832
64 Rice JE, Antic R, Thompson PD. Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease. Mov Disord 2002; 17 (03) 524-527
65 Pietracupa S, Fasano A, Fabbrini G. , et al. Poor self-awareness of levodopa-induced dyskinesias in Parkinson's disease: clinical features and mechanisms. Parkinsonism Relat Disord 2013; 19 (11) 1004-1008
66 Amanzio M, Palermo S, Zibetti M. , et al. Self-unawareness of levodopa induced dyskinesias in patients with Parkinson's disease. Brain Cogn 2014; 90: 135-141
67 Marconi R, Lefebvre-Caparros D, Bonnet AM, Vidailhet M, Dubois B, Agid Y. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov Disord 1994; 9 (01) 2-12
68 Wirdefeldt K, Odin P, Nyholm D. Levodopa-carbidopa intestinal gel in patients with Parkinson's disease: a systematic review. CNS Drugs 2016; 30 (05) 381-404
69 Krack P, Pollak P, Limousin P, Benazzouz A, Deuschl G, Benabid AL. From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity. Brain 1999; 122 (Pt 6): 1133-1146
70 Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord 2005; 20 (Suppl. 11) S11-S16
71 Vijayakumar D, Jankovic J. Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia. Drugs 2016; 76 (07) 759-777
72 Stowe R, Ives N, Clarke CE. , et al; van Hilten. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson's disease patients with motor complications. Cochrane Database Syst Rev 2010; (07) CD007166
73 Morgan JC, Fox SH. Treating the Motor Symptoms of Parkinson Disease. Continuum (Minneap Minn) 2016; 22 (4 Movement Disorders): 1064-1085
74 Mokhles MM, Trifirò G, Dieleman JP. , et al. The risk of new onset heart failure associated with dopamine agonist use in Parkinson's disease. Pharmacol Res 2012; 65 (03) 358-364
75 Perez-Lloret S, Rey MV, Crispo J. , et al. Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients. Expert Opin Drug Saf 2014; 13 (03) 351-360
76 Cannas A, Solla P, Floris G. , et al. Reversible Pisa syndrome in patients with Parkinson's disease on dopaminergic therapy. J Neurol 2009; 256 (03) 390-395
77 Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees AJ. ; Parkinson's Disease Research Group of the United Kingdom. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 2008; 71 (07) 474-480
78 Dewey Jr RB, Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001; 58 (09) 1385-1392
79 Trosch RM, Silver D, Bottini PB. Intermittent subcutaneous apomorphine therapy for ‘off’ episodes in Parkinson's disease: a 6-month open-label study. CNS Drugs 2008; 22 (06) 519-527
80 Haasio K. Toxicology and safety of COMT inhibitors. Int Rev Neurobiol 2010; 95: 163-189
81 Fox SH, Katzenschlager R, Lim S-Y. , et al. The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011; 26 (Suppl. 03) S2-S41
82 Smith KM, Eyal E, Weintraub D. ; ADAGIO Investigators. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability. JAMA Neurol 2015; 72 (01) 88-95
83 Hauser RA, Hsu A, Kell S. , et al; IPX066 ADVANCE-PD investigators. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol 2013; 12 (04) 346-356
84 Stocchi F, Hsu A, Khanna S. , et al. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. Parkinsonism Relat Disord 2014; 20 (12) 1335-1340
85 Pahwa R, Lyons KE, Hauser RA. , et al; APEX-PD Investigators. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. Parkinsonism Relat Disord 2014; 20 (02) 142-148
86 Olanow CW, Kieburtz K, Odin P. , et al; LCIG Horizon Study Group. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014; 13 (02) 141-149
87 Seeberger LC, Hauser RA. Carbidopa levodopa enteral suspension. Expert Opin Pharmacother 2015; 16 (18) 2807-2817
88 Freitas ME, Ruiz-Lopez M, Fox SH. Novel levodopa formulations for Parkinson's disease. CNS Drugs 2016; 30 (11) 1079-1095
89 LeWitt PA, Hauser RA, Grosset DG. , et al. A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease. Mov Disord 2016; 31 (09) 1356-1365
90 Hauser RA, Olanow CW, Dzyngel B. , et al. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease. Mov Disord 2016; 31 (09) 1366-1372
91 Freitas ME, Fox SH. Nondopaminergic treatments for Parkinson's disease: current and future prospects. Neurodegener Dis Manag 2016; 6 (03) 249-268
92 Vorovenci RJ, Antonini A. The efficacy of oral adenosine A(2A) antagonist istradefylline for the treatment of moderate to severe Parkinson's disease. Expert Rev Neurother 2015; 15 (12) 1383-1390
93 Mizuno Y, Kondo T. ; Japanese Istradefylline Study Group. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease. Mov Disord 2013; 28 (08) 1138-1141
94 Hauser RA, Olanow CW, Kieburtz KD. , et al. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol 2014; 13 (08) 767-776
95 Borgohain R, Szasz J, Stanzione P. , et al; Study 016 Investigators. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. Mov Disord 2014; 29 (02) 229-237
96 Borgohain R, Szasz J, Stanzione P. , et al; Study 018 Investigators. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease. Mov Disord 2014; 29 (10) 1273-1280
97 Cattaneo C, Ferla RL, Bonizzoni E, Sardina M. Long-term effects of safinamide on dyskinesia in mid- to late-stage Parkinson's disease: a post-hoc analysis. J Parkinsons Dis 2015; 5 (03) 475-481
98 Pahwa R, Tanner CM, Hauser RA. , et al. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study). Mov Disord 2015; 30 (06) 788-795
99 Eskow KL, Gupta V, Alam S, Park JY, Bishop C. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. Pharmacol Biochem Behav 2007; 87 (03) 306-314
100 Svenningsson P, Rosenblad C, Af Edholm Arvidsson K. , et al. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study. Brain 2015; 138 (Pt 4): 963-973